Foghorn Therapeutics (FHTX) Current Deferred Revenue (2020 - 2026)

Foghorn Therapeutics' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $52.3 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 1.22% year-over-year to $52.3 million in Q1 2026; TTM through Mar 2026 was $52.3 million, a 1.22% increase from a year earlier, with the FY2025 full-year figure at $43.2 million, down 5.29% from the prior year.
• Current Deferred Revenue grew to $52.3 million in Q1 2026 per FHTX's latest filing, from $43.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $337.8 million in Q3 2023 and bottomed at $30.1 million in Q1 2022.
• The 5-year median for Current Deferred Revenue is $33.9 million (2023), against an average of $57.7 million.
• Biggest YoY gain for Current Deferred Revenue was 2494.76% in 2022; the steepest drop was 90.28% in 2022.
• Year by year, Current Deferred Revenue stood at $32.8 million in 2022, then climbed by 5.27% to $34.6 million in 2023, then jumped by 32.0% to $45.6 million in 2024, then slipped by 5.29% to $43.2 million in 2025, then grew by 21.09% to $52.3 million in 2026.
• Per Business Quant, the three latest FHTX Current Deferred Revenue figures stand at $52.3 million (Q1 2026), $43.2 million (Q4 2025), and $65.3 million (Q3 2025).